Accéder au contenu
Merck

P2900000

Prednisone

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1,4-Pregnadiene-17α,21-diol-3,11,20-trione, 1-Cortisone, 17α,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione, Dehydrocortisone

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

A propos de cet article

Formule empirique (notation de Hill) :
C21H26O5
Numéro CAS:
53-03-2
Poids moléculaire :
358.43
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329820154
MDL number:
MFCD00003608
Beilstein/REAXYS Number:
2065301

Principaux documents

Voir toute la documentation
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

InChI key

XOFYZVNMUHMLCC-ZPOLXVRWSA-N

SMILES string

O=C1C=C[C@@]2(C)C(CC[C@]([C@@](CC[C@@]3(C(CO)=O)O)([H])[C@]3(C)C4)([H])[C@]2([H])C4=O)=C1

InChI

1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1

grade

pharmaceutical primary standard

API family

prednisone

manufacturer/tradename

EDQM

mp

236-238 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... NR3C1(2908)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Prednisone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

pictograms

Health hazard
GHS08

signalword

Warning

hcodes

H373

pcodes

P260

Hazard Classifications

STOT RE 2

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Fred Saad et al.
The Lancet. Oncology, 16(3), 338-348 (2015-02-24)
Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. In this phase 3, double-blind
Lindsay Sonstein et al.
The American journal of medicine, 127(11), 1097-1104 (2014-06-15)
Clinical practice guidelines recommend 40-60 mg of prednisone equivalent for 10-14 days for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). However, the amount of corticosteroid prescribed varies widely in clinical practice. Using the electronic health record, we
Charles J Ryan et al.
The Lancet. Oncology, 16(2), 152-160 (2015-01-21)
Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing
Claudine Angela Blum et al.
Lancet (London, England), 385(9977), 1511-1518 (2015-01-23)
Clinical trials yielded conflicting data about the benefit of adding systemic corticosteroids for treatment of community-acquired pneumonia. We assessed whether short-term corticosteroid treatment reduces time to clinical stability in patients admitted to hospital for community-acquired pneumonia. In this double-blind, multicentre
Maxime Touzot et al.
Transplantation, 99(1), 63-68 (2014-07-17)
Donor-specific antibodies (DSA) are considered as reliable biomarkers for antibody-mediated rejection (ABMR) diagnosis. However, it is unclear whether DSA monitoring is necessary and could predict graft outcome after antirejection treatment. We analyzed 28 non-sensitized kidney transplant patients with ABMR associated
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique